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TrafﬁckingABCG2, a metabolite and xenobiotic transporter located at the plasma membrane (predominantly in barrier
tissues and progenitor cells), undergoes a direct progressive endocytosis process from plasma membrane to
intracellular compartments upon binding of 5D3 monoclonal antibody. This antibody is speciﬁc to an external
epitope on the protein molecule and locks it in a discrete conformation within its activity cycle, presumably
providing a structural trigger for the observed internalization phenomenon. Using routine and novel assays,
we show that ABCG2 is endocytosed by a mixed mechanism: partially via a rapid, clathrin-dependent pathway
and partially in a cholesterol-dependent, caveolin-independent manner. While the internalization process is
entirely dynamin-dependent and converges initially at the early endosome, subsequent intracellular fate of
ABCG2 is again twofold: endocytosis leads to only partial lysosomal degradation, while a signiﬁcant fraction of
the protein is retained in a post-endosomal compartment with the possibility of at least partial recycling back
to the cell surface. This externally triggered, conformation-related trafﬁcking pathway may serve as a general
regulatory paradigm for membrane transporters, and its discovery was made possible thanks to consistent
application of quantitative methods.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The human activemembrane transporter ABCG2/BCRP, amember of
the ABC protein superfamily, has been extensively studied due to its
crucial role in determining the distribution of important metabolites
and xenobiotics within the body. While its initial discovery was
connected with the phenomenon of multidrug resistance in cancer [1],
because many commonly used cytotoxic chemotherapeutics are its
transport substrates, it has since emerged as a major determinant of
pharmacokinetics of numerous compounds with varying chemical
structure due to its elevated expression at important tissue interfaces.
It is especially prominent in so-called barrier tissues such as blood–
brain barrier [2] or placenta [3] and at excretory sites such as liver,
kidney or the gut [4–6]. An important physiological function is also
ascribed to the high ABCG2 levels in stem cell populations, where the
transporter is postulated to provide enhanced protection from environ-
mental toxicants [7]. Pathological disruption of ABCG2 activity has been, triﬂupromazine; MDC,
, vincristine; cytoD, cytochalasin
Alexa Fluor; FITC, ﬂuorescein
ophysics, Faculty of Biology and
ha St., 90-237 Lodz, Poland. Tel./linked to metabolite distribution disorders, such as gout (disrupted
urate transport [8]) or reduced vitamin excretion into milk [9]. In
order to efﬁciently execute its directional transport role through cellular
layers, ABCG2 has a pronounced polarized membrane localization with
predominant expression in the apical domain [10].
While ABCG2 is commonly described as having a plasmamembrane
localization, there are reports in the literature about its partial or even
predominant intracellular expression in somemodels and experimental
conditions. Some sequence variants, e.g. the common human polymor-
phismQ141K,misdirects themoleculewith partial folding defects to in-
tracellular aggresomes [11]. In human embryonic stem cells, mild
oxidative stress has been shown to stimulate internalization of ABCG2
[12]. Inhibition of ABCG2 activity with a selected group of molecules
was also demonstrated to induce lysosomal degradation of ABCG2,
presumably after reverse trafﬁcking into intracellular compartments
[13], although this phenomenon is not seen with most generally used
ABCG2 inhibitors. It has also been shown that the PI3K-Akt-mTOR sig-
naling cascade in many cell types is responsible for retaining ABCG2 in
the plasma membrane and inhibition of components of this axis causes
enhanced recycling of the transporter into intracellular vesicles [14]. In
these examples, the ultimate intracellular destination (compartment)
of internalized ABCG2 has rarely been characterized, the fate of the pro-
tein (degraded or not) wasmostly assayed phenomenologically and the
molecular mechanism of translocation has never been studied in any
detail. Also, for many of the described phenomena it is difﬁcult to
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ABCG2 and internalization of molecules originally active on the cellular
surface.
In 2001, a monoclonal antibody speciﬁc for an extracellular epitope
of human ABCG2 was described by the group of Dr. Brian Sorrentino
[7], prepared by immunizing mice with whole mouse ﬁbroblasts heter-
ologously overexpressing human ABCG2 and named clone 5D3. It has
quickly become an indispensable andwidely used tool in ABCG2 studies
due to its ease of use in ﬂow cytometry experiments, and it has grown
into the golden standard in ABCG2 detection in clinical samples [15].
Moreover, extensive work in Dr. Balazs Sarkadi's laboratory has shown
that 5D3 actually binds exclusively to one of the conformations that
ABCG2 assumes during its catalysis cycle [16] and thus it can be used
not only to detect ABCG2 levels, but also to inhibit its activity or to
screen for transporter–drug interactions [17].
While using 5D3 to detect ABCG2 in live cells, we have discovered a
hitherto unreported phenomenon of antibody-triggered internalization
of ABCG2. We have decided to carefully characterize the molecular
mechanism of this trafﬁcking event in view of its potential physiological
signiﬁcance as well as practical importance in interpretation of experi-
mental results. It is well known that some membrane protein groups,
especially cell surface receptors, have complex extracellular ligand
binding-mediated internalization mechanisms which regulate their
expression and activity [e.g. 18,19]. However, no such mechanisms
have yet been identiﬁed for ABC superfamily transporters, although its
members often undergo complex pathways of endocytosis and cycling
between cellular compartments [20]. Endocytosis of membrane pro-
teins is often a complicated process—while receptor-mediated endocy-
tosis triggered by cognate ligands is sometimes simpliﬁed by limiting its
mechanism to the classical clathrin pathway, awareness has increased
recently that themechanisms involvedmay bemanifold and that endo-
cytosis triggered by conformational transformation (e.g. upon antibody
binding) may be an important regulator of availability of active protein
on the cell surface [21,22]. Studying endocytosis in a quantitative
manner is especially challenging technically, since commonly applied
inhibitor-basedmethods are inadequate at characterizingmixedmech-
anisms. For this reason, we have decided to study in depth the mecha-
nism of ABCG2 endocytosis and its intracellular fate, along the way
extending the arsenal of available quantitative methods.
2. Materials and methods
2.1. Cells, reagents and antibodies
A549,MCF-7, G401, HEK293 cell lines purchased fromATCC (Manas-
sas, Virginia, USA) andMDCKII-BCRP purchased from Solvo Biotechnol-
ogy (Budapest, Hungary) were cultured in Dulbecco's modiﬁed Eagle's
medium (DMEM; Life Technologies) containing 10% fetal bovine
serum (FBS; Life Technologies, Carlsbad, CA, USA) at 37 °C with 5%
CO2. HT29 (ATCC)were grown usingMcCoy's 5aMediumModiﬁed sup-
plemented with 10% FBS.
Pitstop 2 and Pitstop 2-negative control and anti-Na+/K+ ATPase
antibody (clone 464.6) were from Abcam (Cambridge, UK), dynasore
was bought from Calbiochem (San Diego, CA, USA). Protease inhibitor
cocktail, protein A/G conjugated paramagnetic beads and 5× Lane
Marker Non-Reducing/Reducing Sample Buffers for SDS-PAGE were
from Thermo Fisher Scientiﬁc (Waltham, MA, USA). All other chemical
inhibitors and reagents were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Anti-ABCG2 (clone 5D3) monoclonal antibody was purchased from
Santa Cruz Biotechnology (Dallas, TX, USA), 5D3-PaciﬁcBlue conjugate
was from BioLegend (San Diego, CA, USA) and 5D3-AF488 from R&D
Systems (Minneapolis, MN, USA). FITC-conjugated antibody against
transferrin receptor was purchased from BD Biosciences (San Jose, CA,
USA). Anti-ABCG2 (clone BXP-34)monoclonal antibody used for immu-
noﬂuorescence was purchased from Enzo Life Sciences (Farmingdale,NY, USA). Polyclonal rabbit anti-ABCG2 antibody (cat. no. AV43649),
monoclonal anti-β-actin antibody (clone AC-74) as well as secondary
HRP-conjugated anti-mouse or anti-rabbit IgG antibodies used for im-
munoblotting were purchased from Sigma-Aldrich. All secondary
Alexa Fluor-conjugated antibodies produced in goat as well as Zenon®
mouse IgG1 labeling reagents conjugated with AF488 and AF555 were
purchased from Life Technologies.
2.2. Genetic constructs
Expression plasmid for TagGFP2–ABCG2 fusion protein was con-
structed using pcDNA6.2/V5-DEST vector backbone (Life Technologies),
coding sequence of human ABCG2 protein, ampliﬁed by high-ﬁdelity
PCR from commercial cDNA (TrueClone vector; Origene, Rockville,
MD, USA) and veriﬁed by full sequencing to be identical to NCBI Refer-
ence Sequence NM_004827.2, as well as coding sequence of TagGFP2
ﬂuorescent protein (Evrogen, Moscow, Russia).
Genetic constructs for transient expression of ﬂuorescently
labeled small GTPase activity mutants were purchased from Addgene
(Cambridge, MA, USA): Arf6-T27N-CFP (dominant negative [45]),
Arf6-Q67L-CFP (constitutively active [45]), EGFP-RhoA-T19N (dominant
negative [46]), EGFP-RhoA-Q63L (constitutively active [46]), EGFP-
Cdc42-T17N (dominant negative [46]), EGFP-Cdc42-Q61L (constitutive-
ly active [46]). Plasmid for Rab5-Q79L-GFP (constitutively active [47])
was a kind gift from Dr. M. Vidal (Univ. Montpellier). pmKate2-lyso
plasmid, lysosome marker, was purchased from Evrogen.
A549 cells were transfected by electroporation with Multiporator
(Eppendorf, Hamburg, Germany) according to themanufacturer recom-
mendations with custom modiﬁcations. Brieﬂy, 1 × 106 cells were
collected and mixed with 10 μg of plasmid DNA in Eppendorf
hypoosmolar buffer. Following electroporation (4 mm cuvette, 500 V,
100 μs, n = 3) and 10 min incubation in room temperature, cells were
suspended in culture medium and used within the next 48 h.
2.3. Immunoblotting
Immunoblotting was performed with standard protocols and
involved SDS-PAGE on 4%–20% pre-cast polyacrylamide gels (BioRad;
Hercules, CA, USA), protein transfer onto polyvinylidene ﬂuoride mem-
brane and probing with primary antibodies and/or appropriate HRP-
conjugated secondary antibodies. Immunolabeling was detected by
chemiluminescence with Super Signal West Femto substrate (Thermo
Fisher Scientiﬁc) and visualized on Multispectral FX Pro In-Vivo Imager
(Carestream; Rochester, NY, USA). For quantiﬁcation, band intensities
were assessed by densitometric analysis using ImageJ software.
In 5D3 accumulation assay aliquots of 1 × 106 of A549 cells were
treated with 5 μg/ml 5D3 antibody or its isotype control (mouse
IgG2b) for respective time periods or 24 h in the absence or presence
of 10 nM baﬁlomycin A1. At indicated time points, cells were cooled
on ice, washed once with ice cold PBS and lysed in buffer A (1% Triton
X-100, PBS pH = 7.4, 5 mM EDTA, 1× protease inhibitor cocktail).
Accumulated antibodywas then puriﬁed from the extract using protein
A/G conjugated paramagnetic beads, eluted with non-reducing sample
buffer and analyzed by immunoblotting. As a reference, known amount
of 5D3 antibody was afﬁnity puriﬁed analogously and 400 pg was used
as a standard for quantiﬁcation.
For ABCG2 and β-actin Western blotting approximately 2 × 106 of
A549 cells pretreated accordingly were used. Cells were collected and
lysed directly with sample buffer supplemented with 5 mM EDTA and
1× protease inhibitor cocktail. Samples equivalent to 10 μg protein
were analyzed.
2.4. Immunoﬂuorescence
Cells were seeded at a density of 2 × 104 cells/well on SensoPlate
(Greiner Bio-One;Monroe, NC, USA) 96-well thin-glass bottomed plates
Fig. 1. 5D3 anti-ABCG2 antibody causes ABCG2 internalization. (A) A549 cells were treated for 30 min with 5D3 antibody (5 μg/ml, mouse IgG2b), washed once and further incubated in
culture medium for 30 min. Incubation was performed on ice (4 °C) or in normal culture conditions (37 °C). As a control, some cells were ﬁxed and medium washed twice prior to the
ﬁrst incubation. All cells were subsequently ﬁxed, permeabilized, and immunostained with secondary anti-IgG2b antibody (AF488-conjugated) as well as with primary antibody against
Na+/K+ ATPase and respective secondary antibody (AF555-conjugated). (B) A549 cells were incubated for 1 h in normal culture conditions with or without addition of 5D3 antibody or
normalmouse IgG2b (5 μg/ml). After ﬁxation and permeabilization, cells were immunostainedwith anti-ABCG2 (BXP-34) and anti-Na+/K+ ATPase antibodies, both ofmouse isotype IgG1,
conjugated directly with Zenon® labeling reagents (AF488 and AF555 respectively). (C) MCF7 andMDCKII-BCRP cells (live or previously ﬁxed)were incubated for 1 h with 5D3 antibody
at different conditions (4 °C or 37 °C). Live cells were subsequently ﬁxed, all were permeabilized and immunostained using AF555-conjugated secondary anti-mouse IgG2b antibody. Scale
bars: 10 μm.
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periments cells were incubated with unlabeled or ﬂuorophore-conju-
gated 5D3 antibody in appropriate culture medium. After medium
removal, in some experiments, cellswere subsequently incubated in ap-
propriate culture medium with a ﬂuorophore-conjugated secondary
antibody. Cells were ﬁxed for 15 min in room temperature with 3.6%
formaldehyde solution in PBS. In the pulse-chase experiment, followingincubation with 0.2 M glycine in PBS, membrane bound fraction of 5D3
antibody was visualized without cell permeabilization by incubation
with Alexa Fluor 555 (AF555) conjugated secondary antibody in buffer
B (1% BSA, 3% goat serum, PBS pH=7.4). Next, cellswere permeabilized
in buffer C (buffer B supplemented with 0.2% Triton X-100) for 10 min
and total bound and internalized 5D3was stainedwith AF488 conjugat-
ed secondary antibody. For all other immunostaining experiments,
Fig. 2. 5D3 induces progressive internalization of ABCG2. (A) A549 cells overexpressing TagGFP2–ABCG2 fusion were treated with 5D3 antibody for 2 h at 37 °C and ﬁxed. (B) A549 cells
were treated for 2 hwith 5D3 antibody, washed and ﬁxed. After permeabilization, cells were immunostainedwith anti-ABCG2 antibody (BXP-34) and AF488-conjugated anti-mouse IgG1
secondary antibody (recognizing the BXP-34 and not the 5D3 antibody). Cell nuclei (blue) are stainedwith Hoechst 33342. (C) A549 cells were incubated for 1 h (ﬁrst endocytosis period)
with medium containing 5D3 antibody, washed and further incubated at 37 °C for 1 h (second endocytosis period) inmedium containing AF555-labeled anti-mouse IgG2b secondary an-
tibody (red, left image). Cells were subsequently ﬁxed, permeabilized, and immunostainedwith secondary anti-IgG2b antibody (AF488-conjugated, green, left image) as well as with pri-
mary antibody againstNa+/K+ATPase and respective secondary antibody (AF555-conjugated, red, right image). Cell nucleiwere stainedwithHoechst 33342 (blue, right image). (D) A549
cells were incubated for 1 h (ﬁrst endocytosis period) with medium containing 5D3-Paciﬁc Blue conjugated antibody (blue, left image), washed and further incubated at 37 °C for 1 h
(second endocytosis period) in medium containing AF555-conjugated anti-mouse IgG2b secondary antibody (red, left image). Cells were subsequently ﬁxed, permeabilized, and
immunostained with primary antibody against Na+/K+ ATPase and respective secondary antibody (AF594-conjugated, red, right image). (E) A549 cells transiently overexpressing
TagGFP2–ABCG2 fusionwere treatedwith 5D3 antibody innormal culture conditions. Fluorescent protein internalization in the same groupof cellswasmonitored by time-course confocal
imaging. Scale bars: 10 μm.
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for 1 h. Proteins of interest were detected by one-hour incubations in
buffer Cwith the speciﬁc primary antibody followed by appropriate sec-
ondary antibody conjugated to AF488, AF555 or AF568. Nuclei were vi-
sualized by 5 min incubation with 5 μM Hoechst 33342 in PBS.
All imageswere obtained using 780 LSM confocalmicroscope (Zeiss;
Oberkochen, Germany)with Plan-Apochromat 63×/1,4Oil DICM27ob-
jective. ZEISSMicroscope Software ZEN2012wasused to calculatemean
ﬂuorescence intensities in respective ﬂuorescence channel within se-
lected region of interest. For the experiment involving transient expres-
sion of ﬂuorescently labeled small GTPase activity mutants, relative
quantiﬁcation of the amount of internalized ﬂuorescent signal was per-
formed by averaging ﬂuorescent intensities in intracellular regions ofinterest selected across the ﬁeld of view and calculating relative inter-
nalization by comparing to analogous ROIs in non-transfected control
cells within the same ﬁeld of view. For colocalization experiments, frac-
tion of 5D3 signal overlappingwith respective marker signal was calcu-
lated for various intracellular regions of interest by dividing number of
pixels positive (exceeding a threshold) for signals in both channels by
totality of pixels positive for 5D3 signal.
2.5. Quantiﬁcation of endocytosis by trypan blue (TB) ﬂuorescence
quenching assay
For quantiﬁcation of 5D3 endocytosis, cells were preincubated for
30 min to 1 h with appropriate inhibitors in DMEMmedium with 10%
Fig. 3.ABCG2 is rapidly internalized upon 5D3 opsonization but its expression level is only
partially decreased. (A) Aliquots of 1 × 106 of A549 cells were treated with 5D3 antibody
(5 μg/ml) for respective time periods in the absence or presence of lysosomal poison
baﬁlomycin A1 (10 nM). For each time point, cells were washed and lysed. After puriﬁca-
tion on protein A/G-conjugated paramagnetic beads, cell-bound 5D3 quantity was
analyzed by immunoblotting with HRP-conjugated anti-mouse IgG antibody. As a refer-
ence, known amount of 5D3 antibody was afﬁnity puriﬁed analogously and 400 pg was
used as a standard for quantiﬁcation. (B) A549 cells were cultured in medium containing
5 μg/ml 5D3 antibody for 24 and 48 h, some cells were also co-incubated with 80 μM
dynasore to inhibit endocytosis. Cells were than harvested and processed for immunoblot
analysis with antibodies against ABCG2 and β-actin. Representative blots and graphs
calculated from three experiments are shown. ABCG2 quantity for each time point was
estimated as a relative value of intensity of ABCG2 band to β-actin band and is presented
on graphs as a fraction of the value calculated for non-treated control cells. Error bars
represent s.e.m. for ABCG2 quantity (n = 3). One-way ANOVA was used to test for
statistical signiﬁcance of differences between all treatments (p b 0.001).
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ments with Pitstop2, Pitstop2-NC and cholesterol sequestrating agents)
and incubated for 1 hwith 5D3 antibody conjugated to AF488 in normal
growth conditions (ﬁnal antibody concentration 5 μg/ml). Next, cells
were washed with medium and bound antibody fraction was allowed
to further internalize for 30 min. For quantiﬁcation of standard cargo
molecules, cells were preincubated for 30 min with inhibitors in HBSS
supplemented with 1% BSA and incubated with FITC-conjugated anti-
body against transferrin receptor (diluted 10×) or with CtxB-AF488
(1 μg/ml) for indicated times in normal growth conditions. Washed
oncewith coldHBSS, living cellswere analyzed immediately by confocal
microscopy. All incubation steps in culture medium/HBSS were per-
formed with the presence of the appropriate inhibitor.
Zeiss 780 LSM confocal microscope with Plan-Neoﬂuar 40×/1.30 Oil
DICM27 objectivewas used to obtain 2 × 2 tile scan images of the same
ﬁeld of view (magniﬁcation 4000×). Care was taken to select ﬁelds of
view with similar cell density (conﬂuence) for various treatments.
Live-cell images were taken before and after quenching external cell
ﬂuorescence with TB added to a ﬁnal concentration of 2.7 mg/ml. Cells
stained internally with TB (necrotic/with compromised membrane in-
tegrity) were excluded from quantitative analysis by identiﬁcation as
ROI (region of interest) based on their red ﬂuorescence (AF568 channel,
imaged separately) and application of inverted ROI masks also in the
green measurement channel (AF488/FITC). Internalized fraction for re-
spective cargo of interest was calculated from ﬂuorescence intensity
data in the green channel and is presented as a percent relative to the
non-inhibited control. All data was processed with ZEISS Microscope
Software ZEN2012 and calculated using the following formula:




Internalized fraction IFð Þ ¼ Mean fluorescence of living cells after TB quenching
Mean fluorescence of living cells before TB quenching
:
3. Results
We have found that in cells expressing surface-localized ABCG2,
incubation with a mouse anti-human ABCG2 antibody (clone 5D3)
causes progressive internalization of the transporter protein from the
plasmamembrane into an intracellular compartment.We ﬁrst observed
this phenomenon by immunoﬂuorescence using ﬂuorescently labeled
secondary antibodies on A549 cells which have been preincubated
with 5D3 at culture conditions. Cells ﬁxed prior to the incubation with
5D3 and cells incubated with 5D3 at 4 °C showed typical membrane
localization of ABCG2. On the other hand, cells incubated at 37 °C
showed intracellular staining (Fig. 1). By using a plasma membrane
marker (Na+/K+ ATPase) counterstaining in the same image ﬁelds,
wewere able to conﬁrm that thiswas a speciﬁc endocytosis-like process
rather than a non-speciﬁc disruption of membrane structure, since the
signal not only became punctate, but also moved inside the cell away
from the plasma membrane. We have proven the speciﬁcity of this ef-
fect by using an antibody isotype control (mouse IgG2b) and subse-
quent detection of ABCG2 after treatment and ﬁxation with another
anti-ABCG2 antibody with a different epitope speciﬁcity, again with
concurrent plasmamembranemarker staining to demonstrate internal-
ization of the ABCG2 signal (Fig. 1B). We also conﬁrmed the universal
character of this phenomenon using a number of other cell lines ex-
pressing endogenous ABCG2 (MCF7, G401, HT29) (as well as overex-
pressing exogenous ABCG2 homologous in HEK293/ABCG2,
heterologous in MDCKII/BCRP) (Fig. 1C and data not shown). In all cell
lines tested, if only ABCG2 protein level was detectable by
immunoﬂuorescence, the membrane transporter was internalized
upon 5D3 binding.
To further conﬁrm the speciﬁcity of this phenomenon, especially
with regard to direct ABCG2 internalization (as opposed to antibodyinternalization with potential other non-speciﬁc targets), we used
A549 cells transiently overexpressing ﬂuorescently labeled ABCG2
(as an N-terminally TagGFP2-tagged fusion protein), incubating them
with unlabeled 5D3 antibody. Cells overexpressing green ﬂuorescent
protein-tagged ABCG2 after 2 h of incubation with 5D3 show clear
vesicular (intracellular punctate) localization of ﬂuorescent protein,
while non-treated cells again show a proper continuous plasma mem-
brane localization of the ABC transporter (Fig. 2A). As an additional
veriﬁcation of speciﬁcity, we tested the trafﬁcking of endogenous
ABCG2 by ﬁxing and detecting the protein using a different antibody
(BXP-34, detecting an intracellular ABCG2 epitope). Unlabeled 5D3
was again used to stimulate internalization, while ABCG2 could subse-
quently be detected independently by speciﬁc immunoﬂuorescence
with BXP-34 and an isotype-speciﬁc secondary antibody (BXP-34 is an
IgG2a, while 5D3 is an IgG2b). This experiment conﬁrmed that most
endogenous ABCG2 is internalized in vesicular structures after 5D3
treatment (Fig. 2B).
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course of ABCG2 internalization. We applied two independent labeling
approaches to demonstrate that trafﬁcking of ABCG2-5D3 complex isFig. 4. ABCG2 internalization can be quantiﬁed to verify effectiveness of various chemical inh
(for Pitstop 2, Pitstop 2-NC and cholesterol sequestrating agents) in DMEM without FBS an
concentration 5 μg/ml) was then bound to the cells for 1 h in normal growth conditions. Nex
for 30 min. Finally, washed once with HBSS, cells were analyzed immediately by confocal m
representative 2 × 2 tile scans of the cells (magniﬁcation 4000×) before and after quenchin
Scale bars: 50 μm. (B) Inﬂuence of various chemical inhibitors on internalization of 5D3 antibod
relative to control experiment (formula in Materials and methods). Error bars represent s.e.m.a progressive, continuous process. A549 cells were pre-treated for 1 h
with 5D3 antibody (unlabeled in Fig. 2C, Paciﬁc Blue-labeled in
Fig. 2D) and then incubated for a further 1 h with an AF555-labeledibitors. (A) A549 cells were preincubated with inhibitors in complete growth medium or
d with 0.2% BSA for 30 min to 1 h. Direct conjugate of 5D3 antibody with AF488 (ﬁnal
t, cells were washed with medium and antibody was allowed to be further internalized
icroscopy. At all steps, inhibitors were supplemented to medium/HBSS. Images show
g external cell ﬂuorescence with trypan blue added to ﬁnal concentration of 2.7 mg/ml.
y calculated from at least two independent experiments and shown as internalized fraction
Results signiﬁcantly different from the control (p b 0.05) are marked with asterisk.
Fig. 4 (continued).
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bound to cell surface ABCG2 during the ﬁrst hour of incubation, but has
not yet been internalized in vesicular structures. In Fig. 2D, after theﬁnal
incubation, total 5D3was visualized (afterﬁxing andpermeabilizing the
cells) by using an AF488-labeled secondary antibody. In both cases, we
added plasmamembrane marker staining (Na+/K+ ATPase) to demon-
strate the path of internalized vesicles into the cell away from themem-
brane (the plasma membrane staining was also pseudocolored red and
shown on a separate image asmerging all 4 channels would have made
theﬁgure illegible). Both these experiments show that a fraction of 5D3-
ABCG2 is efﬁciently occluded during the ﬁrst incubation period (green
in Fig. 2C and blue in Fig. 2D), while another signiﬁcant fraction (red)
is also internalized during the second incubation period, when 5D3 is
no longer present extracellularly (it is important to remember that
both Fig. 2C and Fig. 2D show only the indirectly or directly labeled
5D3 antibody, as opposed to actual visualization of tagged or
immunolabeled ABCG2 in the rest of Fig. 2). The speciﬁcity of this ﬁnd-
ing is demonstrated by full colocalization of both labels in the vesicles
formedduring the second incubationperiod,meaning that this internal-
ization event is still 5D3 binding-driven. Moreover, the progressive
character of theprocess is underscored by a conspicuouslymore periph-
eral localization within the cell of vesicles formed later (with two color
labels). This progressive time course of the investigated processwas fur-
ther conﬁrmed by observing the fate of ﬂuorescently labeled ABCG2
(TagGFP2 fusion) in individual living cells continuously exposed to ex-
tracellular 5D3 (Fig. 2E). Internalization has already started after
15 min of treatment and progresses throughout the experiment.
Many extracellular ligand binding-triggered internalization/
endocytosis events lead to intracellular degradation of the cargo
protein [23]. To determine whether this is also the case for ABCG2,
we monitored the cellular fate of both components of the internalized
5D3-ABCG2 complex in A549 cells. In an experiment where cell-bound
5D3 antibody was afﬁnity-captured and quantiﬁed by immunoblotting,
we conﬁrmed its progressive accumulation with gradual saturation of
total 5D3 amount (Fig. 3A). Inhibition of lysosomal function using
baﬁlomycin A1 led to a dual effect: on the one hand the rate of 5D3
binding and/or internalization decreased, suggesting an endocytotic
event inhibitable by lysosome disruption, on the other hand there was
a moderate increase in the total cellular 5D3 amount after a long(24 h) incubation, suggesting that a fraction of internalized antibody
is normally degraded in lysosomes. With regard to cellular ABCG2
(monitored by immunoblotting), the level of the protein was only
moderately reduced after long-time exposure of cells to 5D3 (Fig. 3B).
This putative degradation event could be quasi-totally inhibited
(the decrease in ABCG2 amount was no longer statistically signiﬁcant)
by dynasore, a general inhibitor of multiple endocytotic pathways
(via dynamin inhibition), suggesting a full dependence of observed
decrease in ABCG2 amount on opsonization-mediated endocytosis.
The next question addressed by us concerned the molecular
mechanisms underlying the observed process, including its relation to
canonical endocytotic pathways. We ﬁrst applied the most commonly
used pharmacological approach, screening various chemical inhibitors
in A549 cells, where ABCG2 endocytosis was triggered by incubation
with unlabeled 5D3 and detected with AF488-labeled secondary anti-
body. We obtained representative microscopic images of cells treated
with routinely used inhibitors of speciﬁc pathways (Supplementary
material — Fig. S1). However, interpretation of representative micro-
scopic images of cells after pharmacological modulation, although
commonly applied in endocytosis research, is relatively subjective and
especially in the case of a mixed mechanism does not yield itself to
easy comparisons and quantitations. In order to introduce an unbiased
quantitative mode of data analysis to support our conclusions, we
developed a novel method based on the known ability of trypan blue
to quench the ﬂuorescence of some dyes coupled with its inability to
pass through intact biological membranes [28]. Our innovation
consisted in using quantitative image analysis to whole microscopic
ﬁelds of view before and after trypan blue addition, allowing us to
calculate speciﬁc values corresponding to the extent of antibody inter-
nalization/occlusion (in this experiment, since unﬁxed live cells had
to be used, the 5D3 antibody was directly labeled with AF488). Thus,
we were able to quantify and statistically test the effect of speciﬁc
inhibitors and inhibitor combinations: Fig. 4A shows representative
low-magniﬁcation ﬁelds of view used in this method, while Fig. 4B
summarizes the quantitative results of our experiments. The results of
this objective evaluation matched inferences subjectively drawn on
the basis of high-magniﬁcation indirect immunoﬂuorescence results
from Fig. S1 and are listed below. Moreover, to validate the applicability
of this novel technique to endocytosis inhibition assays as well as
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performed control experiments with standard cargo molecules for two
endocytotic pathways (transferrin receptor for the clathrin-dependent
pathway and cholera toxin for the cholesterol-sensitive pathway),
conﬁrming the validity of our claims (Supplementary material —
Fig. S2).
We have observed that the post-internalization fate of ABCG2-
containing endosomes depends on the state of cytoskeleton in amanner
coherent with classic endocytosis: disruption of the actin cytoskeleton
(using cytochalasin D, a potent inhibitor of actin polymerization)
interferes mainly with intracellular endosome trafﬁcking (as shown
by altered cellular staining pattern with vesicular clustering at
submembrane sites), with non-signiﬁcant inhibition of antibody-
ABCG2 complex occlusion. On the other hand, interference with
microtubule dynamics (using taxol, a depolymerization inhibitor, or
vincristine and nocodazole, two microtubule disrupting agents)
modulates the fate of ABCG2-containing vesicles at an earlier stage,
both inhibiting their occlusion and altering their location in relation to
the cellular membrane.
Treatment with dynasore, an efﬁcient inhibitor of dynamin GTPase
activity, completely blocked endocytosis resulting in exclusively mem-
brane localization of 5D3–ABCG2 complex and decrease of internalized
fraction to the negative control (4 °C) level. However, since dynamin is
involved both in clathrin-dependent and -independent endocytotic
pathways [24], we used other inhibitors of varying speciﬁcity. Blockers
of clathrin-dependent endocytotic pathway (chlorpromazine,
triﬂupromazine and dansylcadaverin) had a clear inhibitory effect on
ABCG2 endocytosis, but they were not able to completely prevent it
(they were consistently able to inhibit ca. 50% of the extent of internal-
ization), suggesting at least a dual molecular mechanism for this
phenomenon. Supposedly speciﬁc clathrin inhibitor Pitstop 2 had a
strong negative effect on 5D3–ABCG2 internalization, but its negative
control counterpart, presented in literature as ineffective against
clathrin-dependent endocytosis [25], also was inhibitory in our hands
(although less than Pitstop 2 itself), again pointing to the possibility of
parallel involvement of two or more pathways.
We subsequently tested several pharmacological inhibitors of
cholesterol-dependent endocytosis (ﬁlipin, methyl-beta-cyclodextrin
and nystatin) — all of them had a signiﬁcant negative effect on ABCG2
endocytosis to an extent comparable to that of clathrin pathway inhib-
itors, despite having entirely non-overlapping inhibition speciﬁcities.
Since the most widely described cholesterol-dependent pathway is
the caveolar pathway, we tested the more highly speciﬁc caveolar
endocytosis blocker PP2 [26] and found it to be ineffective in stopping
5D3–ABCG2 internalization and trafﬁcking, pointing towards a
clathrin-independent, caveolin-independent, cholesterol-dependent
mechanism as a second component (in addition to the clathrin-
dependent one) of the observed phenomenon. Concurrent application
of inhibitors of the two implicated pathways (clathrin-dependent and
cholesterol-dependent) showed an additive effect with very strong
inhibition (bearing in mind that ca. 80% inhibition of extracellular
ﬂuorescence is observed in the case of cells incubated at 4 °C, this should
be interpreted as complete inhibition of endocytotic events, with theFig. 5. Antibody-binding induced endocytosis of ABCG2 involves both clathrin- dependent and i
AF488 antibody in A549 cells. Prior to cell ﬁxation and imaging, dextran-TRITC (1mg/ml) or alb
respectively. In parallel, some cells were labeled for 30 min in 4 °C with 25 μg/ml transferrin-A
lactosylceramide (LacCer) together with 5D3 antibody (5 μg/ml). Subsequently, these cells we
anti-mouse IgG2b antibody (2 μg/ml). For clarity, 5D3 signal is pictured on all images in green ps
colocalizingwith respective endocytosismarker signalwas calculated for several intracellular re
transfected with the plasmids expressing EGFP or CFP labeled dominant negative (DN) or cons
5 μg/ml 5D3 antibody for 1 h, ﬁxed, permeabilized and stained with AF568 conjugated anti-mo
mutants, relative to that in non-transfected cells is shown in percent. (C) Co-localization of ABC
transfected with pmKate2-lyso vector (lysosome marker) or the plasmid expressing constituti
some/5D3 and early endosome images) antibody for 1 h. Afterﬁxation and permeabilization, AB
anti-ABCG2 (BXP-34) antibody and respective anti-BXP34 secondary antibody conjugatedwith
tive organelle marker signal was calculated for several regions of interest and its mean value isremaining ﬂuorescence due to incomplete quenching and non-speciﬁc
background ﬂuorescence), conﬁrming the independent character of
involvement of these two pathways.
In line with this, genistein, which does not inhibit clathrin-
dependent events at all [27], showed a signiﬁcant inhibitory effect in
our model. The effect of genistein due to its pleiotropic afﬁnity to vari-
ous cell components is difﬁcult to interpret; however, themost relevant
interaction may be its inhibition of tyrosine kinases involved in vesicle
occlusion. It should also be kept in mind for this and other endocytosis
inhibitors that direct interactions with ABCG2 (a multispeciﬁc organic
compound transporter) may modulate the binding afﬁnity of 5D3 and
thus inﬂuence ABCG2 endocytosis by an entirely different mechanism.
On the other hand, incubation with wortmannin, a strong selective in-
hibitor of phosphoinositide-3-kinase (PI3K), had opposite results: the
blocker had little effect on apparent 5D3–ABCG2 internalization itself
(instead of inhibiting, wortmannin actually promoted the occlusion of
ﬂuorescent antibody), but inﬂuenced vesicle size leading to more
diffuse staining.We interpret this as a result of blocking further trafﬁck-
ing of ABCG2-containing early endosomes (coalescence, merging with
lysosomes and further intracellular trafﬁcking) rather than initial
endocytotic events.
To provide further corroboration to our conclusions, we studied the
intracellular colocalization of 5D3–ABCG2 complex with markers and
effectors of potential speciﬁc endocytosis pathways and sites. Fig. 5A
depicts internalized ABCG2 in green pseudocolor and various canonical
cargo molecules in red pseudocolor for ease of interpretation, with
quantitative colocalization coefﬁcients included for objective analysis.
Lack of colocalization with dextran conﬁrms no involvement of pinocy-
totic mechanisms in ABCG2 internalization. Transferrin receptor, a clas-
sic clathrin-coated vesicle cargo, colocalizes partially with ABCG2, with
ca. half of green ABCG2-containing vesicles also stained red. A similar
picture is seen for albumin, which can be endocytosed by a clathrin-
dependent or -independent pathway [29,30]. On the other hand,
cholera toxin B and lactosylceramide, two canonical caveolin pathway
substrates [31,32], show no colocalization with ABCG2, again
conﬁrming conclusions drawn from pharmacological experiments.
Since participation of speciﬁc members of the small GTPase super-
family is often characteristic for individual endocytotic pathways, we
used ectopic transient expression of ﬂuorescently labeled small GTPase
activity mutants (dominant negative and constitutively active variants)
to simultaneously test for the effect of modulation of their activity
on the process of 5D3-ABCG2 endocytosis (by comparing GTPase-
overexpressing and non-overexpressing cells in the same ﬁeld of
view) and for their potential colocalization inside transfected cells
(Fig. 5B). Comparison of internalized ABCG2-related signal in cells was
again performed in a quantitative and objective manner by image
analysis. Thus, we were able to exclude the participation of pinocytotic
(involving Cdc42) and Arf6-dependent pathways in the investigated
phenomenon, while RhoA had an effect (partial inhibition of endocyto-
sis by the constitutively active variant, slight stimulation by the
dominant negative one, partial colocalization with both) consistent
with its reported inhibitory role in clathrin-dependent endocytosis
[33]. With regard to intracellular compartments harboring internalizedndependent pathways. (A) Co-transport of selected endocytosismarkerswith 5D3 or 5D3-
umin-AF647 (50 μg/ml) were co-internalizedwith 5D3-AF488 at 37 °C for 40min and 1 h
F488 or 0.5 μg/ml AF488-conjugated B subunit of cholera toxin or 0.5 μM BODIPY FL C5-
re washed and incubated at 37 °C for 30 min with medium containing AF568-conjugated
eudocolor and respectivemarker ﬂuorescence is show in red. Fraction of 5D3 ﬂuorescence
gions of interest and itsmean value is presented in percent. (B) A549 cells were transiently
titutively active (CA) variants of RhoA, Arf6 and Cdc42 proteins. Cells were incubated with
use IgG2b antibody (red channel). 5D3-induced ABCG2 internalization in cells expressing
G2 signal with selected organellemarkers. Untransfected A549 cells or the cells transiently
vely active mutant of Rab5 protein were incubated with 5 μg/ml 5D3 or 5D3-AF488 (lyso-
CG2proteinwas visualized through the secondary anti-5D3AF568-conjugated antibody or
AF568 (Rab5) or AF488 (lysosome). Fraction of 5D3 ﬂuorescence colocalizing with respec-
presented in percent. Scale bars: 10 μM.
Fig. 6. Fate of ABCG2-5D3 complex within 24 h in pulse-chase type experiment. A549 cells were pretreated with 5 μg/ml 5D3 antibody in normal culture conditions for 30 min, washed
oncewith culture medium and incubated further in culture conditions for 24 h. At indicated time points after antibody washout, cells were washed oncewith PBS and ﬁxedwithout per-
meabilization. To stainmembrane-bound portion of 5D3, cells were incubatedwith AF555 anti-mouse IgG2b secondary antibody andwashedwith PBS. Next, to visualize also internal por-
tion of 5D3 antibody, cells were permeabilized and treated with anti-mouse IgG2b antibody conjugated to AF488. Finally, nuclei were stained with Hoechst 33342 (blue channel).
(A) Representative confocal images from respective time points are shownmerged, in green (total 5D3) or in red (membrane bound 5D3) channels. Scale bars: 10 μM. (A) Mean ﬂuores-
cence intensities (left Y axis) in either green (total 5D3, closed circles) or red (membrane bound 5D3, open circles) channel are plotted against time. Blue triangle markings represent
values for the ratio of total 5D3 to membrane bound 5D3 (right Y axis). Data points are mean ± s.e.m., n = 5.
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cally, wewere able to localize the endocytosed protein to large intracel-
lular vesicles formed from early endosomes upon transient transfection
of cells with constitutively active Rab5 protein (full colocalization) as
well as to lysosomes and early endosomes themselves (partial
colocalization), conﬁrming an intracellular trafﬁcking pathway involv-
ing both of these compartments.
Finally, we designed a two-color experiment involving staining the
non-internalized (membrane-bound) fraction of 5D3–ABCG2 complex
and subsequently (after ﬁxing and permeabilizing) the total cellularamount of the complex with a differently labeled secondary antibody.
This approach was used to follow a pulse of 5D3–ABCG2 complex
quantitatively throughout its cellular fate during 24 h of post-
opsonization incubation (Fig. 6). On representative microphotographs
and image analysis-derived result curves, we again demonstrate the
relatively rapid internalization of the majority of ABCG2-bound
antibody and the slower and partial decrease of total cellular amount,
attributable to degradation of the lysosome-targeted fraction. The
quantitative character of the experiment also allows for observing the
partial and slow recycling of the non-lysosome-targeted fraction back
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tibody and conspicuous decrease of the total to accessible ratio 7 h after
opsonization). After this period, we observe an equilibriumwith no fur-
ther degradation and stable sequestration of the non-recycled part of
the remaining 5D3-ABCG2 complex in a lamellar intracellular
compartment.
4. Discussion
Our study is the ﬁrst to demonstrate an antibody binding-triggered
endocytosis event for a member of the ABC transporter superfamily —
to our knowledge, no similar mechanisms have been described for any
plasma membrane transporter proteins. Moreover, we were able to
characterize this complex process and distinguish two separate endocy-
totic pathways (a clathrin-dependent one and a cholesterol-dependent,
caveolin-independent one) and two possible ultimate intracellular fates
of the internalized ABCG2 protein (degradation or recycling to the
plasma membrane). This was made possible by application of novel
quantitative methodologies, modifying commonly used pharmacologi-
cal inhibition techniques to derive objectively assessed endpoints from
microscopic images.
While the literature contains some descriptions of ABCG2 trafﬁcking
events from the plasmamembrane to intracellular compartments, they
have never been studied in enough detail to reconstruct the responsible
endocytotic pathway(s). Moreover, most, if not all of these data seem to
point to fast withdrawal of the protein from the cell surface with subse-
quent lysosomal degradation, and for most of them the question of
speciﬁcity of the observed phenomenon for ABCG2 has not been
demonstrated directly. In our case, application of amonoclonal antibody
as the endocytosis trigger shows clearly that internalization is speciﬁc to
ABCG2 itself.
In the only case where the internalization-causing agents were
proven to directly bind (and biochemically inhibit) ABCG2 molecules,
cellular ABCG2 was shown to be rapidly and virtually entirely degraded
in lysosomes [13,34]. What is more, authors speculate that the group of
so called dynamic inhibitors may promote transporter degradation via
direct endocytosis to lysosome from plasma membranes and/or by
trafﬁcking from ER membranes immediately following their synthesis.
Here we show that 5D3 binding starts endocytosis processes directly
from the plasma membrane and while in our study it also ultimately
leads to partial lysosomal degradation, a distinct intracellular fate for
antibody-opsonized molecules can be observed as well, with retention
in post-endosomal intracellular vesicles and eventually potential
recycling to the plasma membrane. Thus, it is feasible that the
internalization-promoting action of 5D3 is more general in nature
than that of PZ compounds, with stimuli for broader choice of endocy-
totic pathways and outcomes.
Degradation is also the ultimate fate of ABCG2 in cells exposed to
caffeine and other xanthines, although in contrast to our data, neither
the speciﬁcity of this phenomenon to ABCG2 nor the requirement for
direct interactions between xanthines and ABCG2 have been suggested
[35]. In the case of experiments concerning Akt pathway modulation,
positive correlation was reported between Akt activity and relative
expression of ABCG2 on the cell surface [14,36,37]. However, techniques
used in these studies allow for only circumstantial evidence of ABCG2
internalization from the plasma membrane; moreover, as there is no
suggested direct interaction between Akt pathway elements and
ABCG2, this phenomenon is expected to be non-speciﬁc.
Interestingly, another set of non-speciﬁc factors, those causing mild
oxidative stress, was demonstrated to induce rapid downregulation of
ABCG2 expression on the cell surface with suggestions of partial
lysosomal degradation and partial storage in intracellular compart-
ments for future recycling back to the cell surface [12]. Thus, despite
acknowledgment by the authors that the phenomenon is non-speciﬁc
and that they see it for other membrane proteins as well, it seems
to mimic our speciﬁc, 5D3-mediated endocytosis at least in theintracellular trafﬁcking destinations. It is tempting to conclude that
5D3 binding triggers similar molecular events (the clathrin-dependent
and cholesterol-dependent pathways described in our study) and can
be a convenient and speciﬁc model for stress regulation of ABCG2 local-
ization via its conformational changes.
Within the paradigm of extracellular stimulus-induced endocytosis
of membrane proteins, the phenomenon described in this study is
unique in that the endocytosed protein is neither a bona ﬁde receptor
nor is the internalizing stimulus imitating the binding of a natural
ligand. However, since 5D3 is known to be protein conformation-
speciﬁc and its binding locks the ABCG2 protein in a speciﬁc stage of
its activity cycle [16], we suggest that the overall mechanismof this pro-
cess is analogous to well-known ligand-mediated receptor endocytosis
in that structural changes in a membrane protein, transduced within its
tertiary structure to occlude or reveal distinct conformational motifs at
the intracellular membrane facies, are a signal for the endocytotic
machinery to withdraw the protein from the plasma membrane [38].
Moreover, our identiﬁcation of two distinct molecular mechanisms of
the endocytotic event itself supports the concept of complex recogni-
tion patterns signaling to endocytotic sorting proteins. It is worth noting
that 5D3 has previously been shown not to inﬂuence the multimeric
state of ABCG2 [39]— thus our postulatedmechanism stands in contrast
to numerous receptor endocytosis events triggered speciﬁcally
by antibody- or ligand-mediated dimerization [40]. Still, homology
modeling of ABCG2 structural changes associated with substrate and
nucleotide binding (and, by extension, with 5D3 binding) infer a large
shift in accessibility of intracellular protein surfaces (two main confor-
mations in ABC proteins are termed “open” and “occluded”), complying
with our postulated structural endocytotic trigger [41]. This serendipi-
tous combination of a well-characterized conformational change-
speciﬁc antibody and the body of quantitative data we provide on
intracellular mechanisms of endocytosis and further trafﬁcking of the
antibody–protein complex provides a good opportunity for basic stud-
ies on mechanisms of recognition and sorting of membrane proteins
as endocytotic cargo.
It is important to note that our results in noway contradict the body
of evidence showing 5D3 to be a direct inhibitor of ABCG2-mediated
transport in whole cells by virtue of binding and conformational arrest
[16]. In our hands, 5D3 binding was sufﬁcient to inhibit ABCG2 activity
even under conditions where endocytosis was blocked (data not
shown).
The speciﬁcity of the described mechanism suggests a regulatory
physiological role for the removal of ABCG2 from the plasma mem-
brane. For several other ABC transporters, endocytotic modulation of
the amount of functional protein at the cell surface has been demon-
strated, e.g. ABCC2 can be withdrawn from the apical membrane
domain into an intracellular reservoir as a result of PDZ motif-
mediated interactions [42], while ABCA1 is constitutively endocytosed
and partially degraded, partially recycled, depending on the presence
of its extracellular ligandApoA-I [43]. In all of these cases, the direct trig-
ger for endocytosis is located intracellularly, not extracellularly as in our
study; also the endocytotic pathways used in each case differ from those
indentiﬁed here. However, ABCG2 endocytosis conforms to the overall
paradigm of regulation of transport function at the cell surface by trans-
porter internalization— in our case, most probably linked to conforma-
tional changes.
The complex mechanism described here opens new possibilities of
regulation of function by trafﬁcking for ABC transporters as well as
other transport proteins. It is important to realize that only the applica-
tion of several complementary approaches and innovative quantitative
methods allowed our analysis of this phenomenon. This should serve as
both example and cautionary tale for investigators wishing to elucidate
the backgroundof seemingly straightforward trafﬁcking events. Recent-
ly, other membrane transporters (e.g. Na/K/2Cl cotransporter NKCC2),
previously thought to undergo simple constitutive endocytosis,
were shown to have a more complex and multifactorial trafﬁcking
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titative methods [44]. On a more local scale, the unexpected action of
5D3 antibody, a tool used commonly by scientists studying ABCG2 bio-
chemistry, should be taken under consideration by all those who use it
to assay expression level and/or activity (e.g. in the “5D3 shift”method;
[17]), sinceﬂow cytometric detection does not allow to discriminate be-
tween surface and intracellular localization. Thus, all 5D3 labeling ex-
periments should be performed either on ﬁxed cells or at 4 °C if full
retention of the ABCG2 antigen in the plasma membrane is required.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.04.011.
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